For the quarter ending 2026-03-31, CYTK made $19,355K in revenue. -$208,273K in net income. Net profit margin of -1076.07%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 19,355 | 17,755 | 1,936 | 66,769 |
| Research and development | 95,525 | 104,398 | 99,233 | 112,554 |
| Selling, general and administrative | 104,896 | - | - | - |
| Cost of goods sold | 160 | - | - | - |
| General and administrative | - | 91,723 | 69,458 | 65,721 |
| Collaboration cost of sales | 2,392 | - | - | - |
| Total operating expenses | 202,973 | 196,121 | 168,691 | 178,275 |
| Operating loss | -183,618 | -178,366 | -166,755 | -111,506 |
| Interest expense | - | 11,924* | 11,353 | 11,084 |
| Interest and other expense, net | 14,519 | - | - | - |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | 18,816 | 16,061 | 14,969 | 13,181 |
| Interest and other income, net | 11,022 | 11,470 | 10,248 | 13,001 |
| Change in fair value of derivative liabilities | 1,500 | 900 | 700 | 3,000 |
| Change in fair value of liabilities related to rpi transactions | -1,600 | 13,300 | -2,800 | -14,600 |
| Debt conversion expense | - | 2,351* | 121,249 | - |
| Net loss | -206,031 | -183,031 | -306,178 | -134,370 |
| Unrealized gain on available-for-sale securities, net | -1,838 | 235 | 167 | -851 |
| Foreign currency translation adjustments | -404 | 361 | 25 | -852 |
| Comprehensive loss | -208,273 | -182,435 | -305,986 | -136,073 |
| Basic EPS | -1.67 | -1,489.545 | -2.55 | -1.12 |
| Diluted EPS | -1.67 | -1,489.545 | -2.55 | -1.12 |
| Basic Average Shares | 123,273 | 122,477 | 119,982 | 119,457 |
| Diluted Average Shares | 123,273 | 122,477 | 119,982 | 119,457 |
CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK)